November 19, 2012
Single-Tablet Complera Combo Regimen Proves Comparable to Atripla
Complera proved to be “non-inferior” to, and in some cases more effective than, Atripla in a Phase IIIb study comparing the two single-pill, triple combination antiretroviral therapy regimens among treatment-naive people with HIV, the Business Wire reports. Gilead Sciences, which manufactures Complera (emtricitabine/rilpivirine/tenofovir) announced the findings from its STaR (Single Tablet Regimen) study at the 11th International Congress on Drug Therapy in HIV Infection in Glasgow.
The study compared the rates of undetectable viral loads after 48 weeks of therapy between 394 participants taking Complera, which was approved in the United States in 2011, and another 392 taking Atripla (efavirenz/emtricitabine/tenofovir), the standard of care for treatment-naive people with HIV since its approval in 2006. Overall, 86 percent of those taking Complera and 82 percent of those on Atripla reached an undetectable viral load. Complera maintained a statistically significant advantage among those with a baseline viral load at or below 100,000, with 89 percent reaching undetectable compared with Atripla’s 82 percent. Meanwhile, 80 percent of Complera patients and 82 percent of Atripla patients with baseline viral loads above 100,000 achieved viral suppression.
To read the Business Wire report, click here.
To read Gilead’s release, click here.
Search: HIV, Complera, non-inferior, Atripla, comparble, Phase IIIb, emtricitabine, rilpivirine, tenofovir, STaR, Single Tablet Regimen, 11th International Congress on Drug Therapy in HIV Infection in Glasgow, undetectable viral load, viral suppression.
Scroll down to comment on this story.
[Go to top]